Article | August 27, 2021

Pre-IND Meetings: How To Achieve Success For 505(b)(2)

By Ken Phelps, President and Co-founder, and Angela Drew, Ph.D., Product Ideation Consultant, Camargo, A Division of Premier Research

Meeting iStock-1168175766

One of the greatest mistakes that the Sponsor of a 505(b)(2) can make is to have an unsuccessful Pre-IND meeting. Common errors occur at the Pre-IND meeting because Sponsors and CROs that are more familiar with traditional 505(b)(1) drug development programs fail to appreciate the different goals and the impact of a Pre-IND meeting on a 505(b)(2) program.

The goal of a 505(b)(1) Pre-IND meeting is to introduce the FDA to the novel drug, discuss standard toxicology study results, and propose a first-in-human study. In contrast, a properly prepared and conducted 505(b)(2) Pre-IND meeting presents the proposed strategy and the entire development program, including the justification for leveraging existing data in place of required studies. Therefore, the approval strategy presented in the 505(b)(2) Pre-IND meeting is paramount, requiring productive discussion and alignment with the FDA.

We cannot overemphasize that getting FDA feedback on the entire development program at the Pre-IND meeting is the critical path to success in 505(b)(2) drug development. The Pre-IND meeting must be successful.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: